Table 4.
Prevalence of HBsAg among 1,694 injection drug users who had antibodies to both HBVa and HCV, by HCV infection status and age or duration of drug use, in the San Francisco Bay area between 1998–2000.
| Chronic HCV Infection (HCV RNA positive) |
Resolved HCV Infection (HCV RNA negative) |
Association between HBsAg and HCV RNAb |
||||
|---|---|---|---|---|---|---|
| Age | HBsAg(+)/ Total | (%) | HBsAg(+)/Total | (%) | ORc | 95% CI |
| 18–29 years | 2/44 | 4.55% | 1/18 | 5.56% | 0.81 | 0.07–9.53 |
| 30–39 years | 8/220 | 3.64% | 5/67 | 7.46% | 0.47 | 0.15–1.48 |
| 40–49 years | 15/742 | 2.02% | 14/155 | 9.03% | 0.21 | 0.10–0.44 |
| ≥50 years | 4/387 | 1.03% | 4/61 | 6.56% | 0.15 | 0.04–0.61 |
| Duration of Injection Drug Use | ||||||
| ≤9 years: | 2/79 | 2.53% | 0/30 | 0.00% | undefined | 0.23-∞ |
| 10–19 years | 7/231 | 3.03% | 5/55 | 9.09% | 0.31 | 0.10–1.03 |
| 20–29 years | 14/514 | 2.72% | 9/111 | 8.11% | 0.32 | 0.13–0.75 |
| ≥30 years | 6/530 | 1.13% | 10/99 | 10.10% | 0.10 | 0.04–0.29 |
a
Nineteen subjects with acute HBV infection were excluded.
b
The association between HBsAg and HCV RNA varied by age (p=0.03) and duration of injection drug use (p=0.05) in logistic regression models that controlled for sex, ethnicity, and HIV infection status.